|  | 


IBS Seeks Emergency Use Authorization for Oxford Covid Covid Vaccine in India


The Serum Institute of India on Sunday became the first indigenous company to submit an application to the Comptroller General of Drugs of India (DCGI) seeking an emergency use authorization for the Oxford Covid-19 vaccine in the country citing needs. not covered due to the pandemic and in the interest of the general public, official sources said.

A day earlier, the Indian arm of the US pharmaceutical giant Pfizer became the first to apply for similar approval from the Indian drug regulator for its own Covid-19 vaccine in the country, after obtaining such authorization in the UK and Bahrain.

The phase three clinical trial of the Oxford Covid-19 vaccine, Covishield, is being conducted by the Pune-based Serum Institute of India on Sunday (SII), co-sponsored by the Indian Council of Medical Research (ICMR), in various parts in addition to the clinical studies conducted by Oxford-AstraZeneca in the United Kingdom and Brazil.

Based on the results of the phase two and three clinical trials, IBS, with the help of ICMR, will seek early availability of the vaccine for India, the country’s leading health research body said last month. .

Click here for full coverage of the Covid-19 pandemic

According to the ICMR, IBS has already manufactured 40 million doses of the vaccine under the at-risk manufacturing and storage license it obtained from the DCGI.

Official sources, citing the IBS request, said the firm has stated that data from four clinical studies, two in the UK and one in Brazil and India, show that Covishield is highly effective against symptomatic infections and, most importantly , against serious Covid-19 infections.

The results are in line with other coronavirus vaccines, and due to the huge disease burden, Covishield is expected to alleviate substantial Covid-19 mortality and morbidity, the firm was reported to have said.

“In terms of safety, Covishield was well tolerated with respect to solicited adverse events and was not associated with increased numbers of SAEs and deaths. Most of the requested reactions were mild in severity and resolved without sequelae.

“Therefore, Covishield is safe and well tolerated and can be used effectively for the prevention of Covid-19 in the target population. Therefore, the benefit / risk ratio strongly supports the widespread use of Covishield, ”a source said, citing the app.

In order to introduce an urgently needed Covid-19 vaccine in India, SII, the world’s largest vaccine manufacturer, has established a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

The SII also sent 12 batches of the vaccine to the Central Drug Laboratory (CDL) in Kasauli for analysis, a source said.

“In accordance with our philosophy, we assure you that for Covid-19 vaccines as well, we are committed to making our country ‘aatmanirbhar’ (self-sufficient) and fulfilling our prime minister’s call for ‘vocal for local’ and ‘made in India’ to the world, ”read the application signed by Prakash Kumar Singh, Additional Director of Government and Regulatory Affairs at the Serum Institute of India (SII).

See also | Covid Update: Punjab CM Seeks Clarification on Vaccine; Pfizer seeks approval from India

In view of all these facts and unmet medical needs in the interest of the general public to save millions of people in the country and around the world, the early availability of a Covid-19 vaccine is a necessity, he stated.

“Therefore, in the national interest, we request that you grant us the emergency use authorization of Covishield based on our request and in view of the immediate need for a safe, effective, programmatically appropriate and affordable vaccine for our country. ”The request said.

According to sources, this vaccine is logistically feasible for distribution in both urban and rural areas of the country, since it can be stored between two and eight degrees Celsius, which is an ideal temperature to be kept in cold rooms in the country.

As a swift regulatory response, DCGI on August 2 had given its go-ahead to IBS to conduct the combined phase two and three clinical trials of the Oxford Covid-19 vaccine in the country.

Hindustan Times